Furthermore, Survivin/BIRC5 interacted closely with molecules (Figure 4C) which were shown to regulate stem cell properties in lung adenocarcinomas (SPC25) (28), influence radiosensitivity in lung cancer (AURKA) (29), or mediate anti-EGFR therapy in NSCLC (AURKB) (30). Here, EGFR is linked to non-small cell lung carcinoma.